Skip to content

Study · Case report or series · n = 1 · 2012

7 results

Improvement of psoriasis during exenatide treatment in a patient with diabetes.

Buysschaert M, Tennstedt D, Preumont V

Diabetes & metabolism9 Jan 2012Cited by 38 (Europe PMC)

PMID22227407 (opens in a new tab)DOI10.1016/j.diabet.2011.11.004 (opens in a new tab)PepBankPUB-22227407
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a man with diabetes and psoriasis, weight decreased during exenatide treatment.

    In plain wordsIn a man with diabetes and psoriasis, weight decreased during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient, as expected, lost weight and reduced HbA(1c) levels from 65 mmol/mol to 56 mmol/mol.
    1 context sentence
    Summary · context
    In September 2008, his diabetes treatment was intensified with exenatide (Byetta(®)) to improve poor glycaemic control.
  2. 02HumanCase report or seriesEfficacy outcome

    In a man with diabetes and psoriasis, HbA1c decreased from 65 to 56 mmol/mol during exenatide treatment.

    In plain wordsIn a man with diabetes and psoriasis, HbA1c decreased during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c
    65 mmol/mol
    before exenatide intensification
    HbA1c
    56 mmol/mol
    during exenatide treatment

    Source sentences

    Summary
    The patient, as expected, lost weight and reduced HbA(1c) levels from 65 mmol/mol to 56 mmol/mol.
    1 context sentence
    Summary · context
    In September 2008, his diabetes treatment was intensified with exenatide (Byetta(®)) to improve poor glycaemic control.
  3. 03HumanCase report or seriesEfficacy outcome

    In a man with diabetes, psoriasis improved after exenatide initiation and remained improved at follow-up.

    In plain wordsIn a man with diabetes, psoriasis improved during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePsoriatic plaques
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    PASI score
    3 to 4 PASI score
    1-year follow-up on exenatide (estimated)
    PASI score
    11 PASI score
    before exenatide

    Source sentences

    Summary
    However, after just 1 month of treatment with exenatide, the patient also reported a dramatic improvement in psoriatic plaques that was confirmed at the 1-year follow-up (PASI: estimated at 3-4).
    2 context sentences
    Summary · context
    In September 2008, his diabetes treatment was intensified with exenatide (Byetta(®)) to improve poor glycaemic control.
    Summary · context
    A 61-year-old male patient (BMI: 25.5 kg/m(2)) with T2D treated with metformin and sulphonylureas had also complained, since 1980, of extensive psoriasis that required multiple steroid-based treatments [Psoriasis Area and Sensitivity Index (PASI) score: 11]
  4. 04HumanCase report or seriesOther

    In a man with diabetes, exenatide withdrawal was associated with weight gain.

    In plain wordsIn a man with diabetes, stopping exenatide was linked to weight gain.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseWeight after withdrawal
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Withdrawal of exenatide was associated with weight gain, deterioration of glycaemic control and deterioration of psoriasis (PASI:>10).
    1 context sentence
    Summary · context
    In September 2008, his diabetes treatment was intensified with exenatide (Byetta(®)) to improve poor glycaemic control.
  5. 05HumanCase report or seriesOther

    In a man with diabetes, exenatide withdrawal was associated with worse glycemic control.

    In plain wordsIn a man with diabetes, stopping exenatide was linked to worse blood sugar control.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlycemic control after withdrawal
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Withdrawal of exenatide was associated with weight gain, deterioration of glycaemic control and deterioration of psoriasis (PASI:>10).
    1 context sentence
    Summary · context
    In September 2008, his diabetes treatment was intensified with exenatide (Byetta(®)) to improve poor glycaemic control.
  6. 06HumanCase report or seriesOther

    In a man with diabetes, exenatide withdrawal was associated with worsening psoriasis.

    In plain wordsIn a man with diabetes, stopping exenatide was linked to worse psoriasis.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasePsoriasis after withdrawal
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    PASI score
    > 10 PASI score
    after exenatide withdrawal

    Source sentences

    Summary
    Withdrawal of exenatide was associated with weight gain, deterioration of glycaemic control and deterioration of psoriasis (PASI:>10).
    1 context sentence
    Summary · context
    In September 2008, his diabetes treatment was intensified with exenatide (Byetta(®)) to improve poor glycaemic control.
  7. 07HumanCase report or seriesEfficacy outcome

    In a man with diabetes, psoriasis improved promptly after exenatide reintroduction, with PASI 3.1.

    In plain wordsIn a man with diabetes, psoriasis improved promptly after exenatide restarted.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePsoriasis after reintroduction
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    PASI score
    3.1 PASI score
    after exenatide reinstated

    Source sentences

    Summary
    After reinstating exenatide treatment, the patient again reported a prompt improvement in psoriasis (PASI: 3.1).
    1 context sentence
    Summary · context
    In September 2008, his diabetes treatment was intensified with exenatide (Byetta(®)) to improve poor glycaemic control.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT01687582

Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

Cliniques universitaires Saint-Luc- Université Catholique de Louvainn = 10Jan 2012 to Mar 2013

Type 2 Diabetes · Psoriasis

Trial pageClinicalTrials.govUpdated 12 Mar 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.